Manish Gupta

Behind every number is a parent, a child or a friend, and behind every donor is a ripple effect of healing that reaches far beyond one life.

Abstract: Communicating complex system designs or scientific processes through text alone is inefficient and prone to ambiguity.

How Quantexa's contextual approach and award-winning technology are transforming AML in capital markets.

Abstract: Financial decision-making in multilingual settings demands accurate numerical reasoning grounded in diverse modalities, yet existing

Manish Gupta, Founder & CEO of TestingXperts , a global QE leader with 1,500+ professionals. Champion of AI-led Quality Transformation.

Around this time last year, Bitcoin was being hailed as the market's new version of gold. One year later, a fresh wave of global uncertainty is forcing investors to answer a much bigger question — does crypto really behave like a safe haven when markets panic?

Epcoritamab is a CD3 × CD20 T-cell–engaging bispecific antibody approved for the treatment of various types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) and R/R follicular lymphoma (FL), after at least two lines of systemic therapy. Here, we develop and calibrate repeated time-to-event models to assess the impact of optimized step-up dosing (SUD) regimens and the effect of intravenous fluids and/or corticosteroids on cytokine release syndrome (CRS) risk. The analysis used pooled data from 600 patients with aggressive non-Hodgkin lymphoma (aNHL) and indolent NHL (iNHL) who received subcutaneous epcoritamab in 28-day cycles in the EPCORE® NHL-1 and EPCORE® NHL-3 studies (NCT03625037, NCT04542824). In the calibrated model, prior CAR T cell therapy (125/600 patients [20.8%]) was associated with a 69.7% reduction (95% confidence interval [CI], 38.2–85.2) in the maximum stimulatory effect of epcoritamab on the hazard of Grade ≥2 CRS. Intravenous fluids or dexamethasone during Cycle (C)1 were associated with a 2.89-fold (95% CI, 1.57–5.30) increase in the half-maximal effective plasma concentration of epcoritamab on stimulation (S50). Furthermore, prophylaxis with intravenous fluids and dexamethasone during C1 was associated with a 3.79-fold (95% CI, 1.65–8.73) increase in S50. Simulations show that the use of dexamethasone further reduces Grade ≥2 CRS risk compared with prednisone in patients with aNHL/iNHL. Moreover, a 3-SUD design further reduces CRS risk in patients with iNHL. Overall, our models showed that the approved 2-SUD regimen for R/R LBCL and 3-SUD regimen for R/R FL—together with intravenous fluids and dexamethasone prophylaxis—are adequate to reduce Grade ≥2 CRS risk.

Manish Gupta, Founder & CEO of TestingXperts , a global QE leader with 1,500+ professionals. Champion of AI-led Quality Transformation.

Cryptocurrency technology enables round-the-clock trading of real-world assets like gold and oil. Learn more.

Diary of daily fitness 1. No calls: My days start with chai, taking in the morning stillness and freshness — free from work, no emails or calls.